Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fennec Pharmaceuticals (FENC) FCF Margin: 2011-2025

Historic FCF Margin for Fennec Pharmaceuticals (FENC) over the last 5 years, with Sep 2025 value amounting to 11.98%.

  • Fennec Pharmaceuticals' FCF Margin rose 4361.00% to 11.98% in Q3 2025 from the same period last year, while for Sep 2025 it was -20.59%, marking a year-over-year decrease of 6487.00%. This contributed to the annual value of 56.75% for FY2024, which is 13742.00% up from last year.
  • As of Q3 2025, Fennec Pharmaceuticals' FCF Margin stood at 11.98%, which was up 131.37% from -38.19% recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' FCF Margin ranged from a high of 89,825.00% in Q1 2021 and a low of -332.56% during Q1 2023.
  • Moreover, its 3-year median value for FCF Margin was -42.36% (2023), whereas its average is -57.98%.
  • As far as peak fluctuations go, Fennec Pharmaceuticals' FCF Margin crashed by 8,490,086bps in 2022, and later spiked by 47,957bps in 2024.
  • Fennec Pharmaceuticals' FCF Margin (Quarterly) stood at 5,378.18% in 2021, then slumped by 4,323,041bps to 744.20% in 2022, then plummeted by 79,412bps to -49.92% in 2023, then spiked by 3,132bps to -18.60% in 2024, then soared by 4,361bps to 11.98% in 2025.
  • Its last three reported values are 11.98% in Q3 2025, -38.19% for Q2 2025, and -49.34% during Q1 2025.